Abstract
This review focuses on the emerging role of sensor array-based VOC analysis of exhaled breath, particularly using electronic nose (e-nose) technology, for the early detection of lung cancer. Given the critical importance of early diagnosis in improving lung cancer outcomes, this review emphasizes studies that target Stage I and Stage II lung cancer. Traditional diagnostic methods often fall short in identifying lung cancer at its earliest, most treatable stages, leading to high mortality rates. E-nose technology, inspired by the human olfactory system, offers a non-invasive, rapid, and potentially cost-effective approach to detecting volatile organic compounds (VOCs) in exhaled breath, which serve as biomarkers for lung cancer. Through a systematic review of the literature, we initially identified 193 studies related to e-nose-based breath analysis for lung cancer detection. After applying rigorous selection criteria, focusing specifically on studies involving early-stage lung cancer and excluding those using alternative VOC analysis methods, 12 studies were deemed eligible for inclusion. These studies demonstrate the significant potential of e-nose technology in detecting subtle changes in VOC profiles associated with early-stage lung cancer. This review synthesizes the current state of knowledge, highlights recent advancements, and discusses the challenges and future directions of integrating e-nose technology into clinical practice for early lung cancer detection. The findings underscore the promise of e-nose technology as a valuable tool in the ongoing effort to reduce lung cancer mortality through earlier diagnosis.

This publication has 41 references indexed in Scilit: